Monthly Archives: September 2020

New study: Supprelin LA and less-expensive Vantas implant equally effective for blocking puberty in trans youth

Posted on September 30, 2020 by Zinnia Jones

Previously, I’ve noted some rather concerning confusion among anti-trans activists on the subject of implanted puberty-blocking medications used in trans adolescents. Brie Jontry, a spokesperson for anti-trans hub 4thWaveNow, characterized the Vantas brand of once-yearly histrelin acetate implant as a … Continue reading →

Posted in Uncategorized | Leave a comment

Update on cases of lymphoma linked to textured breast implants in transgender women (BIA-ALCL)

Posted on September 30, 2020 by Zinnia Jones

I’ve previously covered emerging findings on breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL), a type of non-Hodgkin’s lymphoma caused by the textured surfaces of some implants used in breast augmentation surgeries. Textured surfaces have been used in some breast implants to … Continue reading →

Posted in Breast, Health care, Oncology, Surgery, Transfeminine | Tagged , | Leave a comment

Lower doses of cyproterone acetate may be similarly effective for blocking testosterone, with a lower risk of adverse effects

Posted on September 1, 2020 by Zinnia Jones

Previously: Cyproterone acetate and meningioma risk in trans women (March 2018) Update on case reports: Cyproterone acetate and meningioma in trans women (November 2018) Disclaimer: I am not a medical professional and this is not medical advice. Cyproterone acetate (CPA) … Continue reading →

Posted in Endocrinology, Oncology, Progestogens, Transfeminine, Transgender medicine | Tagged , , , | 1 Comment